Literature DB >> 3040807

Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells.

P K Peterson, B Sharp, G Gekker, C Brummitt, W F Keane.   

Abstract

Mounting evidence suggests that opiate addiction and stress are associated with impaired cell-mediated immunity. We tested the hypothesis that morphine and the endogenous opioid beta-endorphin (beta-END), a pituitary peptide released in increased concentrations during stress, can suppress the production of the key macrophage-activating lymphokine interferon-gamma (IFN-gamma) by cultured human peripheral blood mononuclear cells (PBMNC). Using a radioimmunoassay to measure IFN-gamma, we found that exposure of PBMNC to biologically relevant concentrations of both opioids significantly inhibited IFN-gamma generation by cells stimulated with concanavalin A and varicella zoster virus. Studies of the mechanism of suppression revealed (a) a classical opioid receptor is involved (suppression was antagonized by naloxone and was specific for the NH2 terminus of beta-END), (b) monocytes are the primary target cell for opioids (monocyte-depleted lymphocyte preparations showed little suppression), and (c) reactive oxygen intermediates (ROI) and prostaglandin E2 are important mediators (scavengers of ROI and indomethacin eliminated the suppression). Based on these findings we suggest that opioid-triggered release of inhibitory monocyte metabolites may play a role in the immunodeficiency associated with narcotic addiction and stress.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040807      PMCID: PMC442309          DOI: 10.1172/JCI113140

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  65 in total

Review 1.  Enkephalins and endorphins as modifiers of the immune system: present and future.

Authors:  J Wybran
Journal:  Fed Proc       Date:  1985-01

2.  Beta-endorphin modulates immune functions. A review.

Authors:  E G Fischer; N E Falke
Journal:  Psychother Psychosom       Date:  1984       Impact factor: 17.659

3.  Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages.

Authors:  B M Sharp; W F Keane; H J Suh; G Gekker; D Tsukayama; P K Peterson
Journal:  Endocrinology       Date:  1985-08       Impact factor: 4.736

Review 4.  Effects of opiates and neuropeptides on immune functions.

Authors:  R E Faith; N P Plotnikoff; A J Murgo
Journal:  NIDA Res Monogr       Date:  1984

Review 5.  Psychic distress and the immune response.

Authors:  E S Tecoma; L Y Huey
Journal:  Life Sci       Date:  1985-05-13       Impact factor: 5.037

6.  Defective IFN-gamma production in the human neonate. II. Role of increased sensitivity to the suppressive effects of prostaglandin E.

Authors:  N Wakasugi; J L Virelizier; F Arenzana-Seisdedos; B Rothhut; J M Huerta; F Russo-Marie; W Fiers
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

Review 7.  Stress, affective disorders, and immune function.

Authors:  B A Schindler
Journal:  Med Clin North Am       Date:  1985-05       Impact factor: 5.456

8.  Morphine depression of T cell E-rosetting: definition of the process.

Authors:  R M Donahoe; J J Madden; F Hollingsworth; D Shafer; A Falek
Journal:  Fed Proc       Date:  1985-01

9.  Suppression of T lymphocyte chemotactic factor production by the opioid peptides beta-endorphin and met-enkephalin.

Authors:  S L Brown; D E Van Epps
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

Review 10.  Proopiomelanocortin-derived peptides in the immune system.

Authors:  J E Blalock
Journal:  Clin Endocrinol (Oxf)       Date:  1985-06       Impact factor: 3.478

View more
  33 in total

Review 1.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

2.  Opiate abuse and viral replication in hepatitis C.

Authors:  Kevin Moore; Geoff Dusheiko
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

Review 3.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

Review 4.  Modulation of immune function by morphine: implications for susceptibility to infection.

Authors:  Sabita Roy; Jinghua Wang; Jennifer Kelschenbach; Lisa Koodie; Josephine Martin
Journal:  J Neuroimmune Pharmacol       Date:  2006-03       Impact factor: 4.147

Review 5.  Drugs of abuse, immune modulation, and AIDS.

Authors:  Guy A Cabral
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-28       Impact factor: 4.147

6.  Effect of chronic morphine administration on circulating T cell population dynamics in rhesus macaques.

Authors:  William D Cornwell; Mark G Lewis; Xiaoxuan Fan; Jay Rappaport; Thomas J Rogers
Journal:  J Neuroimmunol       Date:  2013-09-20       Impact factor: 3.478

7.  Morphine suppresses intracellular interferon-alpha expression in neuronal cells.

Authors:  Qi Wan; Xu Wang; Yan-Jian Wang; Li Song; Shi-Hong Wang; Wen-Zhe Ho
Journal:  J Neuroimmunol       Date:  2008-06-17       Impact factor: 3.478

8.  Naloxone Diminishes the Virulence and Modifies the Cellular Immune Responses of BALB/c Mice Infected with Leishmania major.

Authors:  Mohammad Hossein Alimohammadian; Farhad Riazi-Rad; Mahsa Asadi-Tat; Sima Darabi; Haiedeh Darabi; Vahid Khaze; Fariborz Bahrami; Soheila Ajdary
Journal:  Acta Parasitol       Date:  2020-11-19       Impact factor: 1.440

9.  Upregulation of SOCS-3 and PIAS-3 impairs IL-12-mediated interferon-gamma response in CD56 T cells in HCV-infected heroin users.

Authors:  Li Ye; Xu Wang; David S Metzger; Eric Riedel; Luis J Montaner; Wenzhe Ho
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

Review 10.  Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression.

Authors:  M J Finley; C M Happel; D E Kaminsky; T J Rogers
Journal:  Cell Immunol       Date:  2008-02-14       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.